Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …

In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …

Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …

The immune system plays a significant role in multiple sclerosis. While MS was historically
thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Objective To determine factors (including the role of specific disease modulatory treatments
[DMTs]) associated with (1) baseline,(2) on-treatment, and (3) change (from treatment start to …